BioSpace News Archive

Sutro Biopharma, Inc. announced that on September 15, 2021, the Compensation Committee of Sutro’s Board of Directors granted restricted stock unit awards representing an aggregate of 150,000 shares of Sutro common stock and stock options to purchase an aggregate of 145,000 shares of Sutro common stock to 3 new employees.

Basilea Pharmaceutica Ltd. announced the reporting of the updated efficacy and safety results from cohort 1 of the phase 2 study FIDES-01, which evaluated its fibroblast growth factor receptor inhibitor, derazantinib, in patients with FGFR2 fusion-positive advanced or metastatic intrahepatic cholangiocarcinoma, a type of bile duct cancer, at the Congress of the European Society for Medical Oncology, taking place as a virtual meeting from 16 to 21 September 2021.

Genital warts are a common sexually transmitted infection caused by the human papillomavirus (HPV).

Depth filtration takes advantage of the thickness (depth) of the filter media to remove liquid droplet, submicron particles, suspended particles, colloidal material, and soluble materials from its carrying liquid.

UV light disinfection systems are non-touch disinfection device used to kill various infectious pathogens present on medical devices, health care equipment, and health care facilities such as operating rooms and patient wards.

Trevena, Inc. announced that Carrie Bourdow, President and Chief Executive Officer of Trevena, will present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit being held virtually from September 20th – 23rd.

Gritstone bio, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, announced updated results from the Phase 1/2 study evaluating the safety, immunogenicity, and clinical activity of GRANITE individualized neoantigen immunotherapy in advanced solid tumors.

Ginkgo Bioworks, Inc. and Soaring Eagle Acquisition Corp., a special purpose acquisition company, announced the closing of their previously announced business combination.

Enveric Biosciences announced the closing of its acquisition of MagicMed Industries Inc., a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine and other molecular derivatives with applications across multiple indications, in an all-stock transaction.

Galapagos NV today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca